Fiche société
Actio Biosciences, Inc.
Traitements, essais et publications liés.
Traitements5programmes
Essais2liés
Publications6liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| ABS-1230This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy | Épilepsie | Phase 1 | À vérifier | Australia | À vérifier |
| OmeprazoleThis first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants. | Épilepsie | Phase 1 | À vérifier | Australia | À vérifier |
| VoriconazoleThis first in human trial will evaluate the safety, tolerability, and pharmacokinetics of single ascending doses, multiple ascending doses, and fed and fasted doses of ABS-1230 given orally compared with placebo in adult healthy participants. | Épilepsie | Phase 1 | À vérifier | Australia | À vérifier |
| ABS-1230This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy | Épilepsie | Phase 2 | À vérifier | United States | À vérifier |
| ABS-1230This trial will evaluate the safety, tolerability, pharmacokinetics, and clinical activity of ABS-1230 compared with placebo in participants with KCNT1-related epilepsy | Épilepsie | Phase 1 | À vérifier | Australia | À vérifier |
Essais cliniques
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| ABS-1230 | Épilepsie | Phase 1 | NCT07156201 | A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ABS-1230 Given Orally Compared With Placebo in Healthy Participants Aged 18 to 55 Years | RECRUITING |
| ABS-1230 | Épilepsie | Phase 2 | NCT07600736 | KYRON — A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of ABS-1230 in Pediatric and Young Adult Participants With KCNT1-related Epilepsy | RECRUITING |
Publications
6| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Voriconazole | Triazole resistance in clinical Aspergillus fumigatus isolates in India, a multicenter surveillance study. | Diagnostic microbiology and infectious disease | ||
| Voriconazole | Repurposing the antispasmodic drug pinaverium bromide as a novel antifungal agent and synergist against . | Virulence | ||
| Voriconazole | Population genomics reveals a long-term increase in azole resistance associated with the emerging cluster AZR among causing invasive infections. | Emerging microbes & infections | ||
| Omeprazole | Vitamin D in synergy with triple therapy to eradicate Helicobacter pylori infection in mice via the c-Raf/MEK/ERK pathway. | Tissue & cell | ||
| Omeprazole | From traditional medicine to advanced sensing: A natural Fraxin-based supramolecular probe for visual pH detection and in vivo gastrointestinal imaging. | Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy | ||
| Omeprazole | Gastroprotective effect of Daphniphyllum calycinum Benth.-Polygonum hydropiper L. against gastric mucosal injury through autophagy activation and apoptosis suppression. | Journal of ethnopharmacology |